Subcommittee on the Microbiome

Subcommittee on the Microbiome

Mission Statement

The mission of the HESI Microbiome Subcommittee is to examine gut microbial-host dynamics to understand how the gut microbiome affects human health, drug efficacy and xenobiotic toxicity. The focus is to identify markers contributing to or resulting from disease or organ damage, including:

alterations of the microbial community structure and microbiome function;

The Gut Microbiome: Markers of Human Health,

Drug Efficacy and Xenobiotic Toxicity

The gut microbiome is believed to play an important role in human health in areas as diverse as brain function and the immune system. Exploring host-microbiome interactions will provide a mechanistic understanding and enable new insights in human diseases (i.e., their diagnosis, prognosis and treatment) and new perceptions of xenobiotic efficacy and/or toxicity. This workshop will review the science and initiate discussions on multiple topics, including a) identification of biomarkers of toxicity for alterations in gut microbial function, b) if changes in the microbiome can affect efficacy of medicines and c) if exposure to xenobiotics can eventually result in a disease state through changes in the microbiome. Conclusions from his workshop will help determine where the data gaps are so that researchers can start answering these questions.

WORKSHOP GOALTo identify data gaps that can be addressed to help determine if alterations in the gut microbiome have an effect on human health.

WORKSHOP AIMS1. To discuss and review the current science on the gut microbiome and identify areas of interest regarding its role in human health2. To discuss our understanding on how xenobiotic toxicity affects the microbiome3. To understand if there are biomarkers of disease or organ damage due to: - Alterations of microbiome structure and function - Endogenous microbial metabolites

CONFIRMED SPEAKERS

Elena Biagi, University of Bologna Kun Lu, University of North Carolina, Chapel HillCarrie Brodmerkel, Janssen Jeremy Nicholson, Imperial College London Mark Brown, Cleveland Clinic Andrew Patterson, Pennsylvania State UniversityCarl Cerniglia, US FDA, NCTR Gary Perdew, Pennsylvania State UniversityEugene Chang, University of Chicago Joseph Petrosino, Baylor College of MedicineJulia Cui, University of Washington Nathan Price, Institute for Systems BiologyAnna Mae Diehl, Duke University Mohan Raizada, University of FloridaRodney Dietart, Cornell University Barbara Reherhman, NIDDKAaron Erickson, University of MissouriMarijke Faas, University of Groningen

The Gut Microbiome: Markers of Human Health,

Drug Efficacy and Xenobiotic Toxicity

The gut microbiome is believed to play an important role in human health in areas as diverse as brain function and the immune system. Exploring host-microbiome interactions will provide a mechanistic understanding and enable new insights in human diseases (i.e., their diagnosis, prognosis and treatment) and new perceptions of xenobiotic efficacy and/or toxicity. This workshop will review the science and initiate discussions on multiple topics, including a) identification of biomarkers of toxicity for alterations in gut microbial function, b) if changes in the microbiome can affect efficacy of medicines and c) if exposure to xenobiotics can eventually result in a disease state through changes in the microbiome. Conclusions from his workshop will help determine where the data gaps are so that researchers can start answering these questions.

WORKSHOP GOALTo identify data gaps that can be addressed to help determine if alterations in the gut microbiome have an effect on human health.

WORKSHOP AIMS1. To discuss and review the current science on the gut microbiome and identify areas of interest regarding its role in human health2. To discuss our understanding on how xenobiotic toxicity affects the microbiome3. To understand if there are biomarkers of disease or organ damage due to: - Alterations of microbiome structure and function - Endogenous microbial metabolites

CONFIRMED SPEAKERS

Elena Biagi, University of Bologna Kun Lu, University of North Carolina, Chapel HillCarrie Brodmerkel, Janssen Jeremy Nicholson, Imperial College London Mark Brown, Cleveland Clinic Andrew Patterson, Pennsylvania State UniversityCarl Cerniglia, US FDA, NCTR Gary Perdew, Pennsylvania State UniversityEugene Chang, University of Chicago Joseph Petrosino, Baylor College of MedicineJulia Cui, University of Washington Nathan Price, Institute for Systems BiologyAnna Mae Diehl, Duke University Mohan Raizada, University of FloridaRodney Dietart, Cornell University Barbara Reherhman, NIDDKAaron Erickson, University of MissouriMarijke Faas, University of Groningen